APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 055550 Name of the Signatory :- S M KRISHNANDesignation :- Company Secretary and Compliance Officer APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Shareholding for the Period Ended December 31, 2021
Apollo Hospitals Enterprise Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 05, 2022 for Mrs Suneeta Reddy Covid-19: Apollo Hospitals begins vaccination for children aged 15-18
Timely vaccination would help children return to normal life, says Prathap C Reddy APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Closure of Trading Window
As per annexure enclosed
J&K signs MoU with Apollo for setting up multi-specialty hospital in Jammu
Jammu and Kashmir on Tuesday signed an MoU with Apollo Hospitals for the establishment of a multi-specialty hospital in Jammu.
Apollo Hospitals keeps well in all its segments
The hospitals business has seen a strong rebound. Rising non-covid revenue has helped normalize the business mix APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Apollo Hospitals Enterprise Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
Buy Apollo Hospitals; target of Rs 5900: Motilal Oswal
Motilal Oswal is bullish on Apollo Hospitals recommended buy rating on the stock with a target price of Rs 5900 in its research report dated December 21, 2021. 